Photo by Mathurin NAPOLY / matnapo on Unsplash
Prof Chirantan Chatterjee
University of Sussex Business School Professor Chirantan Chatterjee has been appointed to a technical expert committee in South Africa tasked with creating a national vaccine strategy for the country and the greater African region. This appointment recognises Professor Chatterjee’s 18 years of experience working in the global pharmaceutical and healthcare markets in the US, EU, and India.
The South African government’s Department of Science, Technology and Innovation’s Vaccine Innovation and Manufacturing Strategy Committee aims to improve vaccine development and distribution by learning from the challenges faced during COVID-19 and encouraging cooperation between developing countries for future pandemics. Professor Chatterjee’s expertise will be instrumental in shaping policies related to vaccine pricing and universal health insurance, ensuring equitable access to vaccines for citizens in the Global South.
Professor Chatterjee’s involvement builds upon the University of Sussex’s longstanding relationship with South Africa. Recently, the University has engaged in discussions on South Africa’s national innovation and economic growth strategies. Professor Chatterjee’s work with the South African government aligns with the University of Sussex Business School’s global outlook and research focus on health. The Business School considers this initiative as a perfect opportunity to contribute to global health and development, particularly in these challenging times.
Professor Chirantan said: “I am honoured to be part of this expert committee. This role allows me to leverage my experience in global pharmaceutical and healthcare markets to contribute to equitable vaccine access and health policy in the Global South. Ongoing collaboration between the University of Sussex Business School and South Africa is a testament to our shared commitment to innovation and development. I look forward to the impactful work ahead.”
Professor Chatterjee is also a Visiting Professor at the Max Planck Institute for Innovation and Competition, where his work on global life sciences and the bioeconomy complements his role on the South African vaccine strategy committee.